Article Per Year (5 Year)
p-Index From 2021 - 2026
1.908
P-Index
This Author published in this journals
All Journal Nusantara Medical Science Journal Universa Medicina Indonesian Journal of Obstetrics and Gynecology (Majalah Obstetri dan Ginekologi Indonesia) Jurnal Ilmiah Kesehatan Cermin Dunia Kedokteran Indonesian Journal of Cancer Cermin Dunia Kedokteran
Kartiwa Hadi Nuryanto
Department Of Obstetrics And Gynecology, Faculty Of Medicine, University Of Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Public Health

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search

 1   2 
Clinicopathological Profile and Disease-Free Survival in Stage I-II Endometrial Cancer at Cipto Mangunkusumo Hospital Muhammad Rizkinov Jumsa; Kartiwa Hadi Nuryanto; Tricia Dewi Anggraeni; Tantri Hellyanti
Nusantara Medical Science Journal Vol. 10 No. 2 (2025): Volume 10 Issue 2, July - December 2025
Publisher : Faculty of Medicine, Hasanuddin University.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20956/nmsj.v10i2.48383

Abstract

Introduction: This study aimed to describe the clinicopathological profile and evaluate the disease-free survival (DFS) of patients with FIGO 2009 stage I–II endometrioid endometrial cancer, and to determine the prognostic value of key factors, emphasizing lymphovascular space invasion (LVSI) and tumor grade. Methods: A retrospective cohort of 111 patients treated between January 2017 and December 2022 was analyzed. Variables included age, menopausal status, BMI, depth of myometrial invasion, LVSI, and tumor grade. Survival was estimated using the Kaplan–Meier method; associations were assessed with Fisher’s exact test, and independent prognostic factors were identified using multivariate Cox regression analysis Results: The median follow-up for the 111 patients was 32 months. Most were stage IB (42.4%), aged 45–60 years (46.8%), postmenopausal (73%), and obese (63%). Stage-specific DFS rates were: Stage IA – 94.6% (1-year), 87.8% (2-year), 87.8% (3-year); Stage IB – 93.6% (1-year), 91.0% (2-year), 91.0% (3-year); Stage II – 92.6% (1-year), 88.9% (2-year), 88.9% (3-year). LVSI positivity (15.3%) and high tumor grade emerged as the strongest prognostic factors. Multivariate analysis confirmed LVSI as an independent predictor across all stages, with hazard ratios ranging from 3.85 in stage IA to 4.25 in stage IB and 12.5 in stage II (p<0.05). In stage II, LVSI-positive patients showed a 57.1% 3-year DFS versus 100% in LVSI-negative patients. Conclusions: LVSI and tumor grade are independent, interrelated prognostic markers in early-stage endometrial carcinoma. Their integration into risk stratification refines adjuvant therapy guidance. Implementation requires standardized pathological reporting and efficient referral systems to improve long-term surveillance adherence.
Co-Authors Achmad Kemal Harzif Ampri, Irfan Arieqal Hatta Andi Darma Putra Anggaraeni, Tricia Dewi Argy, Gabriella Binathara, Geraldus Sigap Gung Edward Christopher Yo Eka R Gunardi Fitriyadi Kusuma Gatot Purwoto Gita Pratama Hariyono Winarto Hariyono Winarto Hellyanti, Tantri JM Seno Adjie Kanadi Sumapradja Kemal Akbar Suryoadji Laila Nuranna Lestari, Silvia Werdhy Marcel Elian Suwito Michael Adrian Mila Maidarti Muhammad Haekal Muhammad Haekal Muhammad Rizkinov Jumsa Shelly, Vannesa Sini, Kieran Pasha Ivan Soloan, Garry Sugianto Sugianto Suryoadji, Kemal Akbar Talya, Natasha Tantri Hellyanti Tofan Widya Utami Tofan Widya Utami Tofan Widya Utami Tricia Dewi Anggraeni Tyagitha, Galuh Anindya Utami, Tofan Widya Wulandari, Anisa Saphira Yanfaunas, Atika Mahira Yo, Edward Christopher